Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Stone, R.; Mandrekar, S.; Sanford, B.; Laumann, K.; Geyer, S.; Bloomfield, C.; Thiede, C.; Prior, T.; Döhner, K.; Marcucci, G.; Lo‐Coco, F.; Klisovic, R.; Wei, A.; Sierra, J.; Sanz, M.; Brandwein, J.; D. de Witte, T.; Niederwieser, D.; Appelbaum, F.; Medeiros, B.; Tallman, M.; Krauter, J.; Schlenk, R.; Ganser, A.; Serve, H.; Ehninger, G.; Amadori, S.; Larson, R.; Döhner, H.

doi:10.1056/NEJMoa1614359

Public

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

Shared by NobleBlocks on Jun 23, 2017 • 12:00 AM UTC

Authors:

R. Stone

S. Mandrekar

B. Sanford

Abstract

Background Patients with acute myeloid leukemia (AML) and a FLT3 mutation have poor outcomes. We conducted a phase 3 trial to determine whether the addition of midostaurin — an oral multitargeted kinase inhibitor that is active in patients with a FLT3 mutation — to standard chemotherapy would prolon...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!